Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
GLOBETECH PUBLISHING
JIB

Thermo Fisher Sells Businesses Before Purchase of Life Technologies

By BiotechDaily International staff writers
Posted on 21 Jan 2014
On January 6, 2014, Thermo Fisher Scientific (Waltham, MA, USA) announced a USD 1.06 billion sale of multiple business units to GE Healthcare (Little Chalfont, United Kingdom), as a condition of regulatory approval for Thermo Fisher's acquisition of Life Technologies (Carlsbad, CA, USA).

The businesses sold to General Electric's life sciences arm include Thermo Fisher's cell culture, gene modulation, and magnetic beads units, which Thermo Fisher believes to have generated a combined USD 250 million in revenue over the past year. Goldman Sachs analysts said they do not expect the deal to have a major impact on Thermo Fisher's continued growth.

The divestiture has been expected since November 2013 when Thermo Fisher announced that it had reached an agreement with the European Commission to approve the purchase of Life Technologies.

If not for the sales announced on January 16, 2014, the acquisition would have left Thermo Fisher with almost 50% of the cell culture market. In the US, the Federal Trade Commission (FTC) approval for the Life Technologies purchase is still pending, but Thermo Fisher has stated that they do not expect the FTC to raise any additional hurdles.

In the genomics world, the USD 13.6 billion acquisition of Life Technologies has focused on Life's Ion Torrent arm, the gene sequencing unit that has been making gains against market leader Illumina. Ion Torrent has been noted for its rapid development and heavy investments in R&D, including a yet-unreleased semiconductor chip for the Ion Proton sequencer that could make the instrument competitive in high-throughput sequencing with Illumina's HiSeq 2500.

Thermo Fisher has the resources to pour even more funding into the Ion Torrent line. However, it is unknown what the new parent company's intentions are for Life Technologies, which has a huge portfolio of biotechnology products, any number of which will fit into Thermo Fisher's existing pipelines in sample prep, synthetic biology, forensics, and other research and clinical applications. Thermo Fisher is not known for its emphasis on R&D; in fact, in recent years, the smaller Life Technologies has occasionally outspent Thermo Fisher in this area.

Related Links:

Thermo Fisher Scientific
GE Healthcare
Life Technologies



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Blocking the activity of HSP101 may imprison the malaria parasite inside its protective vacuole within the red blood cell. In the electron micrograph, the malaria parasites appear in blue and uninfected red blood cells are shown in red (Photo courtesy of the [US] National Institute of Allergy and Infectious Diseases).

Heat Shock Protein Plays Critical Role in Malaria Parasite Protein Trafficking

A pair of recent papers described the molecular operators that enable the malaria parasite Plasmodium falciparum to export a large variety of proteins across the parasitophorous vacuolar membrane (PVM)... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.